New York, June 8, 2026, 09:07 (EDT)
- Tango reported a 92% objective response rate for its vopimetostat-daraxonrasib combo in evaluable pancreatic cancer patients.
- Tango shares spiked 45% in premarket trading, Reuters said. Benzinga put the stock at $30, up 48.37%.
- The company is moving the combo into Phase 3 for first-line MTAP-deleted pancreatic cancer.
Tango Therapeutics shares rose in premarket trading Monday. The company posted positive early results for its pancreatic cancer drug combo and said it aims to advance the treatment into late-stage trials.
Tango’s latest readout puts the company closer to a Phase 3 trial, the kind of large study it will need for approval. The company said the results back moving fast with vopimetostat alongside Revolution Medicines’ daraxonrasib in first-line MTAP-deleted pancreatic cancer. MTAP deletion is a genetic loss in some tumors.
Tango shares jumped before the Nasdaq opened. Reuters said the stock was up 45% in premarket trade. Benzinga cited Benzinga Pro data showing the shares higher by 48.37% at $30. Reuters
Tango said 11 out of 12 response-evaluable pancreatic ductal adenocarcinoma patients had tumors shrink enough to qualify as an objective response. Objective response rate, or ORR, is the percentage of patients whose tumors were reduced by a set threshold. The company also put six-month progression-free survival at 90%, so 90% of patients were alive and the disease had not advanced at the six-month mark.
Vopimetostat, Tango’s oral PRMT5 inhibitor, goes after an enzyme that cancer cells with MTAP deletions need. Tango puts the rate of MTAP deletions at 10% to 15% across human cancers. It says about 40% of pancreatic cancers and 15% of lung cancers have this mutation.
Chief Executive Malte Peters said the trial offered “encouraging signals of durability” and might point to a “chemotherapy-free option” for patients with MTAP-deleted pancreatic cancer. Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, called pancreatic cancer a “largely intractable disease.” Tango Therapeutics, Inc
Revolution Medicines, which provided the RAS(ON) inhibitors used in the trial, is in focus around the news. RAS(ON) inhibitors are a class of drugs that target active RAS proteins—a frequent driver of cancer growth. Reuters pointed out the Tango data landed just a week after Revolution said its drug daraxonrasib doubled survival and boosted quality of life in pancreatic cancer.
Tango says it’s planning more than just Revolution. In its first-quarter update, the company outlined a Phase 1/2 study with vopimetostat paired with Erasca’s ERAS-0015, targeting another RAS combination in the second half of 2026.
Tango says its balance sheet gives it some breathing space for now. As of March 31, the company reported $379.8 million in cash, cash equivalents and marketable securities, enough to fund operations into 2028. Net loss for the first quarter came in at $45.5 million, or 32 cents a share.
But the data set is both early and small. The main PDAC result for the daraxonrasib combo came from just 12 evaluable patients. Larger trials may not see the same response rates. The SEC filing mentioned risks like regulatory feedback, trial timing, side effects, and funding. Tango reported several grade 3 adverse events—rash, stomatitis/mucositis, fatigue—but didn’t see any related grade 4 or 5 events, and no patients stopped treatment due to adverse events.
Tango said it plans to finalize the Phase 3 trial design in the second half of 2026. It will also release vopimetostat lung cancer monotherapy data, report first TNG456 glioblastoma data, and present pancreatic cancer combination data at a scientific conference.
